01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Competing interests
Authors’ contributions
Background
Methods
Patient population
Infection control strategy
Definitions
Strain typing
Survey
Statistics
Results
Patient demographics
Category
|
Epidemic
P. aeruginosa (
n = 30)
|
Cohort with unique chronic
P. aeruginosa infection
|
Entire CF cohort without epidemic
P. aeruginosa
|
||
---|---|---|---|---|---|
UNI (
n = 67)
|
P Value
|
ENT (
n = 112)
|
P Value
|
||
Age
|
32.81 (IQR 29.5–39.3)
|
29.61 (IQR 24.9–41.9)
|
0.13
|
29.5 (IQR 23.7–42.5)
|
0.10
|
Gender (Female)
|
17 (56.7 %)
|
40 (60 %)
|
0.48
|
60 (53.4 %)
|
0.84
|
Pancreatic Sufficient
|
1 (3.3 %)
|
6 (9 %)
|
0.3
|
19 (17 %)
|
0.07
|
F508 del Homozygous
|
18 (60 %)
|
37 (56 %)
|
0.44
|
56 (50 %)
|
0.42
|
≥1 F508del allele
|
27 (90 %)
|
57 (66 %)
|
0.5
|
93 (83 %)
|
0.56
|
Status post lung transplant
|
12 (40 %)
|
9 (13.4 %)
|
0.005
|
12 (10.7 %)
|
<0.001
|
Age at transplant
|
29 (IQR 24.5–31.2)
|
33.27 (IQR 23.4–35.7)
|
0.53
|
33.9 (IQR 23.3–38.3)
|
0.41
|
Chronic Infection Status
|
|||||
P. aeruginosa
|
30 (100 %)
|
67 (100 %)
|
N/A
|
67 (59.8 %)
|
<0.001
|
S. aureus (MSSA)
|
5 (20 %)
|
29 (43.7)
|
0.009
|
61 (54.5 %)
|
<0.001
|
MSSA as sole pathogen
|
0
|
0
|
N/A
|
21 (18.8 %)
|
0.007
|
S. aureus (MRSA)
|
1 (3 %)
|
3 (5 %)
|
0.63
|
8 (7 %)
|
0.68
|
S. maltophilia
|
0
|
0
|
N/A
|
2 (2 %)
|
1
|
Non-tuberculous mycobacteria
|
0
|
6 (9 %)
|
0.1
|
17 (15.1 %)
|
0.02
|
M. abscessus complex
a
|
0
|
2 (3 %)
|
0.48
|
10 (9 %)
|
0.12
|
M. avium complex
|
0
|
4 (6 %)
|
0.22
|
7 (6 %)
|
0.34
|
A. xylosoxidans
|
0
|
0
|
N/A
|
2 (2 %)
|
1
|
B. cepacia complex (Bcc)
b
|
1 (3 %)
|
2 (3 %)
|
0.67
|
4 (3.5 %)
|
1
|
Aspergillus fumigatus
|
2 (6.6 %)
|
2 (3 %)
|
0.36
|
5 (4.5 %)
|
0.64
|
No chronic pathogens
|
0
|
0
|
N/A
|
6 (5.3 %)
|
0.34
|
Risk for acquisition of ePA
Exposure
|
Epidemic
P. aeruginosa (
n = 30) (%)
|
Compared to those with chronic unique
P. aeruginosa strains
|
Compared to the rest of the clinic cohort irrespective of
P. aeruginosa status
|
||||
---|---|---|---|---|---|---|---|
UNI (
n = 66)(%)
|
OR
|
P value
|
ENT
|
OR (CI)
|
P Value
|
||
(
n = 112)
|
|||||||
(%)
|
|||||||
Attended CF Camps
|
19/30 (63)
|
5/66 (8)
|
8.36 (3.45–20.3)
|
<0.001
|
8/104 (8)
|
8.23 (4–16.9)
|
p < 0.001
|
Personal Involvement in prior fundraising events
|
16/30 (53)
|
18/66 (27)
|
1.96 (1.17–3.28)
|
0.02
|
30/103 (29)
|
1.83 (1.16–2.87)
|
p = 0.02
|
Family member involved in CF fundraising events
|
16/30 (53)
|
25/65 (38)
|
1.38 (0.88–2.19)
|
0.128
|
37/102 (36)
|
1.47 (0.96–2.24)
|
p = 0.14
|
Have you ever lived with some one with CF
|
9/30 (30)
|
21/65 (32)
|
0.93 (0.48–1.78)
|
1
|
26/102 (25)
|
1.17 (0.62–2.23)
|
p = 0.64
|
Attended School or work with someone with CF
|
6/30 (20)
|
19/66 (29)
|
0.70 (0.31–1.56)
|
0.46
|
20/103 (19)
|
1.03 (0.46–2.33)
|
p = 1
|
Shared Medical Devices with someone with CF
|
6/30 (20)
|
10/66 (15)
|
1.32 (0.53–3.30)
|
0.57
|
12/103 (12)
|
1.47 (0.96–2.24)
|
p = 0.14
|
Shared Meals with someone with CF (outside of Camps)
|
10/30 (33)
|
17/66 (26)
|
1.29 (0.67–2.48)
|
0.47
|
21/103 (20)
|
1.17 (0.62–2.23)
|
p = 0.64
|
Intimate Contact with someone with CF
a
|
3/30 (10)
|
5/66 (8)
|
1.32 (0.34–5.17)
|
0.7
|
4/103 (4)
|
1.03 (0.46–2.33)
|
p = 1
|
Knowledge regarding infection transmission potential
Question
|
Epidemic
P. aeruginosa (
n = 30)
|
Compared to those with chronic unique
P. aeruginosa strains
|
Compared to the rest of the clinic cohort irrespective of
P. aeruginosa status
|
||
---|---|---|---|---|---|
UNI (
n = 66)
|
P Value
|
ENT (
n = 112)
|
P value
|
||
Individuals with CF can spread germs to each other
|
6 (IQR 6–7)
|
7 (IQR 6–7)
|
0.54
|
7 (IQR 6–7)
|
0.87
|
B cepacia is a germ that can be spread
|
7 (IQR6-7)
|
6 (IQR 4–7)
|
0.04
|
6 (IQR 4–7)
|
0.03
|
Pseudomonas is a germ that can spread
|
6(6–7)
|
6 (6–7)
|
0.49
|
6 (6–7)
|
0.34
|
Staphylococcus is a germ that can spread
|
6 (6–7)
|
6 (5–7)
|
0.18
|
6 (5–7)
|
0.15
|
People with CF can spread infection via cough
|
7 (6–7)
|
6 (5–7)
|
0.14
|
6 (6–7)
|
0.2
|
Contaminated clinic surfaces such as chairs and desks can spread infection
|
6 (6–7)
|
6 (5–7)
|
0.57
|
6 (5–7)
|
0.36
|
Healthcare workers can spread infection
|
6 (6–7)
|
6 (5–7)
|
0.52
|
6 (5–7)
|
0.4
|
Patients with lung transplants are at risk of acquiring infections
|
7 (6–7)
|
6 (5–7)
|
0.3
|
6 (6–7)
|
0.26
|
Patients with lung transplants are at risk of spreading infection
|
5 (4–6)
|
6 (4–7)
|
0.97
|
6 (4–7)
|
0.65
|
Situation
|
Epidemic
P. aeruginosa (
n = 30)
|
Compared to those with chronic unique
P. aeruginosa strains
|
Compared to the rest of the clinic cohort irrespective of
P. aeruginosa status
|
||
---|---|---|---|---|---|
Situations associated with risk of transmitting infections
|
UNI (
n = 66)
|
P Value
|
ENT (
n = 112)
|
OR, P value
|
|
Patients not washing hands
|
6 (6–7)
|
6 (5–7)
|
0.69
|
6 (6–7)
|
0.84
|
Health care workers not washing hands
|
7 (6–7)
|
7 (6–7)
|
0.91
|
7 (6–7)
|
0.87
|
Clinic environment between patients
|
5 (4–7)
|
6 (5–7)
|
0.07
|
6 (4.5–7)
|
0.13
|
Exposure to another CF patient coughing
|
6 (6–7)
|
7 (5–7)
|
0.66
|
7 (5–7)
|
0.87
|
Exposure to another CF patient talking
|
4 (2–4)
|
5 (2–6)
|
0.1
|
4 (2–6)
|
0.16
|
Spirometry performed in a PFT laboratory
|
6 (4–7)
|
6 (4–7)
|
0.98
|
4 (4–6)
|
0.63
|
Importance of various measures in reducing risk of infection transmission
|
|||||
Segregation of patients in to separate rooms
|
6 (5–7)
|
7 (5–7)
|
0.19
|
7 (6–7)
|
0.11
|
All patients washing hands/sterilizing with alcohol upon entry and exit from rooms
|
7 (7–7)
|
7 (6–7)
|
0.11
|
7 (6–7)
|
0.10
|
Patients wearing a mask in hospital common areas
|
4 (3–6)
|
5 (3–7)
|
0.44
|
5 (3–6)
|
0.98
|
Cleaning of examination rooms between patients
|
7 (6–7)
|
7 (5–7)
|
0.59
|
7 (5–7)
|
0.41
|
Avoiding
direct physical contact with other patients
|
6 (3–7)
|
6 (5–7)
|
0.49
|
6 (5–7)
|
0.49
|
Avoiding
any contact with other CF individuals
|
3 (2–4)
|
5 (2–7)
|
0.05
|
5 (2–7)
|
0.04
|